Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed et al.
Our knowledge regarding pathological and treatment resistance mechanisms involved in depression is far from understood. Sexual dimorphism in this topic is well acknowledged. However, the need to highlight sex-based discrepancies is unmet. Ketamine, the dissociative anesthetic, has emerged as a rapid antidepressant. This chapter reviewed sexual dimorphism in pharmacological and genetic models of...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Bhargab Deka, Biswajit Dash, Alakesh Bharali et al.
1 citation
Ketamine has been extensively used in the medical field for more than 50 years, but its exact mechanism of action remains unknown. It’s used to induce dissociative anesthesia (a state of profound analgesia, amnesia with light sleep, immobility, and a sense of disassociation from one’s own body and surroundings). Clinical studies on ketamine as a dissociative anesthetic, a model for psychosis,...
Ketamine Revisited - New Insights into NMDA Inhibitors
September 14, 2022
Patrycja Kleczkowska, Malgorzata Zaremba
5 citations
Ketamine is a derivative of phencyclidine with unique anesthetic, analgesic, as well as antidepressant pharmacological properties. Despite its clinical use, ketamine is classified on the list with new psychoactive substances having psychedelic properties. The abuse trend of ketamine increasing globally, and it became a common club drug over the past few decades. Of note, recreational use of...
The Journal of Clinical Psychiatry
September 12, 2022
P. Oliver, A. Snyder, R. Feinn et al.
Introduction: Few studies have been published to date exploring the effectiveness of ketamine for treatment-resistant depression (TRD) in large clinical samples. We report on the clinical outcomes of a large cohort treated with ketamine as part of clinical practice. Methods: Deidentified electronic chart data were obtained from a multisite private ketamine infusion clinic for 424 patients with...
Anesthesiology
September 12, 2022
Albert Dahan, Erik Olofsen, Thomas K. Henthorn et al.
3 citations
We thank Bowdle et al.1 for their interest in our article,2 and for the important issue they raise, paraphrased as follows: what is the best anthropocentric description of the "mind-altering" effects of a heterogeneous group of compounds and drugs that act at the brain and cause significant changes in mental state. The group of drugs that we are referring to includes N-methyl-d-aspartate (NMDA)...
Molecular Psychiatry
September 7, 2022
Rebecca B Price, Nicholas Kissel, Andrew Baumeister et al.
80 citations
Abstract Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar...
bioRxiv Preprint Server
September 6, 2022
Tommaso Di Ianni, Matine M. Azadian, Sedona N. Ewbank et al.
2 citations
preprint
Subanesthetic ketamine rapidly and robustly reduces depressive symptoms in patients with treatment-resistant depression. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of ketamine in depression may...
Molecules
September 1, 2022
Rosa Estrada-Reyes, Daniel B Quero-Chávez, Salvador Alarcón-Elizalde et al.
Melatonin (MEL), an indolamine with diverse functions in the brain, has been shown to produce antidepressant-like effects, presumably through stimulating neurogenesis. We recently showed that the combination of MEL with ketamine (KET), an NMDA receptor antagonist, has robust antidepressant-like effects in mice, at doses that, by themselves, are non-effective and have no adverse effects. Here,...
Journal of Affective Disorders
September 1, 2022
Melody J Y Kang, Gustavo Vazquez
BACKGROUND Major Depression is the leading cause of disability worldwide. A cohort of patients do not respond adequately to available antidepressants, leading to treatment-resistant depression (TRD). We evaluated the antidepressant efficacy of an acute intravenous ketamine treatment (0.5 mg/kg) for patients with unipolar TRD, and measured peripheral blood-based biomarkers associated with...
Journal of Affective Disorders
September 1, 2022
Madeline Brendle, Reid Robison, D. Malone
OBJECTIVE The aim of this study was to estimate the cost-effectiveness of esketamine nasal spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) in the US. METHODS We used a Markov model with a 1-month cycle length, and we estimated quality-adjusted life years (QALYs), costs (2020 USD), and incremental cost-effectiveness ratios (ICER) of esketamine...